IMRA
Closed
Imara Inc
48.05
+0.04 (+0.08%)
Last Update: 01 Jul 2025 23:10:00
Yesterday: 48.0071
Day's Range: 47.36 - 48.6416
Send
sign up or login to leave a comment!
When Written:
21
Imara Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for patients with rare genetic disorders. The company's lead product candidate, IMR-687, is being developed for the treatment of sickle cell disease and beta-thalassemia. IMR-687 is a selective phosphodiesterase 9 (PDE9) inhibitor that has demonstrated the ability to reduce red blood cell sickling, decrease inflammation, and improve endothelial function in preclinical studies. Imara Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company went public in 2019 and is traded on the NASDAQ under the ticker symbol "IMRA."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








